Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation

被引:11
|
作者
Yamazaki, Osamu [1 ]
Ubara, Yoshifumi [1 ]
Suwabe, Tatsuya [1 ]
Nakanishi, Shohei [1 ]
Hoshino, Junichi [1 ]
Sawa, Naoki [1 ]
Hayami, Noriko [1 ]
Yamanouchi, Masayuki [1 ]
Takemoto, Fumi [1 ]
Kenmei, Takaichi [1 ]
Masuoka, Kazuhiro [2 ]
Oohashi, Kenichi [3 ]
机构
[1] Toranomon Gen Hosp, Nephrol Ctr, Takatsu Ku, Kanagawa 2120015, Japan
[2] Toranomon Gen Hosp, Dept Hematol, Kawasaki Ku, Kanagawa, Japan
[3] Toranomon Gen Hosp, Dept Pathol, Kawasaki Ku, Kanagawa, Japan
关键词
AL amyloidosis; Autologous peripheral blood stem cell transplantation; SCT; High-dose melphalan; Proteinuria; VAD; (vincristine; doxorubicin; and dexamethasone); NEPHROTIC SYNDROME; SURVIVAL; SUPPORT;
D O I
10.1007/s10157-009-0198-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We report a 58-year-old Japanese man with primary systemic AL amyloidosis who achieved disappearance of proteinuria including Bence-Jones protein (lambda-type) after two courses of VAD therapy (vincristine, doxorubicin, and dexamethasone) and subsequent high-dose melphalan, followed by autologous peripheral blood stem cell transplantation. Because this patient did not have any apparent amyloidosis-related heart or liver damage and met all of the eligibility criteria for this therapy, this treatment was performed. Both proteinuria and M-protein disappeared completely, and he is doing well clinically at 19 months after treatment. However, amyloid deposits were still found in the kidneys, including the glomeruli and tubulointerstitium, when renal biopsy was done at 8 months after treatment. In the future, we may reach a time when clinical remission corresponds to histological remission.
引用
收藏
页码:522 / 525
页数:4
相关论文
共 50 条
  • [1] Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation
    Osamu Yamazaki
    Yoshifumi Ubara
    Tatsuya Suwabe
    Shohei Nakanishi
    Junichi Hoshino
    Naoki Sawa
    Noriko Hayami
    Masayuki Yamanouchi
    Fumi Takemoto
    Takaichi Kenmei
    Kazuhiro Masuoka
    Kenichi Oohashi
    Clinical and Experimental Nephrology, 2009, 13 : 522 - 525
  • [2] High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis
    Sanchorawala, Vaishali
    ACTA HAEMATOLOGICA, 2020, 143 (04) : 381 - 387
  • [3] Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis
    Sanchorawala, Vaishali
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2012, 2 (01): : 9 - 17
  • [4] HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AL AMYLOIDOSIS PATIENTS
    Michael, M.
    Kastritis, E.
    Delimbassi, S.
    Kyrtsonis, M. C.
    Papadimetriou, C.
    Apostolides, I.
    Panayiotidis, P.
    Harhalakis, N.
    Pangalis, G.
    Dimopoulos, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 469 - 470
  • [5] An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
    V Sanchorawala
    DG Wright
    DC Seldin
    LM Dember
    K Finn
    RH Falk
    J Berk
    K Quillen
    M Skinner
    Bone Marrow Transplantation, 2001, 28 : 637 - 642
  • [6] An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
    Sanchorawala, V
    Wright, DG
    Seldin, DC
    Dember, LM
    Finn, K
    Falk, RH
    Berk, J
    Quillen, K
    Skinner, M
    BONE MARROW TRANSPLANTATION, 2001, 28 (07) : 637 - 642
  • [7] Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
    Seldin, David C.
    Anderson, Jennifer J.
    Skinner, Martha
    Malek, Karim
    Wright, Daniel G.
    Quillen, Karen
    Finn, Kathleen
    Oran, Betul
    Sanchorawala, Vaishali
    BLOOD, 2006, 108 (12) : 3945 - 3947
  • [8] High-dose melphalan and autologous stem cell transplantation after VAD chemotherapy for systemic light chain (AL) amyloidosis
    Perz, JB
    Schoenland, S
    Hundemer, M
    Linke, RP
    Ho, AD
    Goldschmidt, H
    BONE MARROW TRANSPLANTATION, 2004, 33 : S159 - S159
  • [9] Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation
    Gono, T
    Matsuda, M
    Dohi, N
    Hoshi, K
    Tada, T
    Sakashita, K
    Koike, K
    Aizawa, M
    Ikeda, S
    INTERNAL MEDICINE, 2003, 42 (01) : 72 - 77
  • [10] High-dose melphalan followed by autologous stem cell transplantation in patients with primary systemic (AL) amyloidosis
    Knop, S
    Lengerke, C
    Hebart, H
    Kanz, L
    Einsele, H
    BONE MARROW TRANSPLANTATION, 2004, 33 : S165 - S165